Ajanta Pharma Ltd share price
Ajanta Pharma Ltd (AJANTPHARM) is a stock listed on India's exchanges (NSE & BSE). It is commonly tracked under the Pharma theme. On Traddx you can view its live price, interactive candlestick charts with 20/50/200-day moving averages and golden/death-cross detection, quarterly results, analyst price targets, peer comparison, and the smart-money signal — which star investors hold it and who is buying it on today's bulk/block deals tape.
Ajanta Pharma Limited value chain — customers, suppliers & competitors
Ajanta Pharma develops, manufactures, and markets specialty pharmaceutical finished dosages, operating as a branded generic player across India, the US, and emerging markets like Africa.
🛒 Customers — who buys from Ajanta Pharma Limited
- Doctors and Hospitals — Specialty pharmaceutical formulations (branded generics)
- Global Distributors and Retail Pharmacies — Generic finished dosages
⛓️ Suppliers — raw materials & inputs
- Active Pharmaceutical Ingredients (APIs) — Chemical compounds and raw drug ingredients
- Packaging materials — Blister packs, cartons, and bottles
⚔️ Competitors — other sellers
- Lupin Limited — Competes in branded generics and US generic formulations; larger scale globally.
- Laurus Labs Limited — Competes in APIs and formulation manufacturing.
- Emcure Pharmaceuticals — Competes strongly in domestic specialty pharmaceutical formulations.
🔀 Other suppliers to its customers
- Sun Pharmaceutical Industries — Supplies competing specialty and generic formulations to similar markets.
- Dr. Reddy's Laboratories — Alternative supplier of generic drugs and finished dosages to global pharmacies.
🤝 Peers that share its suppliers
- Torrent Pharmaceuticals — Shares similar raw material and API suppliers for domestic specialty formulations.
- Alkem Laboratories — Procures comparable chemical inputs and packaging materials for branded generics.
This value-chain map is AI-researched from public sources; company links and any figures are estimates, not official company disclosures. Not investment advice.